Skip to main content
. 2018 Sep 21;97(38):e12462. doi: 10.1097/MD.0000000000012462

Figure 1.

Figure 1

Study protocol. When disease activity score reached low disease activity or remission evaluated by disease activity score-28–erythrocyte sedimentation rate (DAS28-ESR), administration of etanercept (ETN) was discontinued (ETN-Off). If DAS28-ESR became moderate or higher in these patients, ETN was readministered with observation every 2 months (ETN-On). Patients who could not achieve low disease activity within 6 months were considered to be discontinued from the study.